According to Brunton [23], treatment for MetS and type 2 diabetes has been transformed by synthetic GLP-1 receptor agonists (like liraglutide and semaglutide) and DPP-4 inhibitors (like sitagliptin). Here, DPP4 is linked to metabolic syndrome.